Department of Neurosurgery, Washington University School of Medicine, Saint Louis, MO 63110, USA.
Department of Applied Biology, University of Science & Technology, Techno City, Killing Road, Baridua 9th Mile 793101, Meghalaya, India.
Int J Mol Sci. 2021 Sep 28;22(19):10468. doi: 10.3390/ijms221910468.
Enzyme therapies are attracting significant attention as thrombolytic drugs during the current scenario owing to their great affinity, specificity, catalytic activity, and stability. Among various sources, the application of microbial-derived thrombolytic and fibrinolytic enzymes to prevent and treat vascular occlusion is promising due to their advantageous cost-benefit ratio and large-scale production. Thrombotic complications such as stroke, myocardial infarction, pulmonary embolism, deep venous thrombosis, and peripheral occlusive diseases resulting from blood vessel blockage are the major cause of poor prognosis and mortality. Given the ability of microbial thrombolytic enzymes to dissolve blood clots and prevent any adverse effects, their use as a potential thrombolytic therapy has attracted great interest. A better understanding of the hemostasis and fibrinolytic system may aid in improving the efficacy and safety of this treatment approach over classical thrombolytic agents. Here, we concisely discuss the physiological mechanism of thrombus formation, thrombo-, and fibrinolysis, thrombolytic and fibrinolytic agents isolated from bacteria, fungi, and algae along with their mode of action and the potential application of microbial enzymes in thrombosis therapy.
在当前情况下,由于酶具有亲和力高、特异性强、催化活性和稳定性好等特点,因此作为溶栓药物引起了人们的极大关注。在各种来源中,由于具有成本效益比高和大规模生产的优势,应用微生物来源的溶栓和纤维蛋白溶解酶来预防和治疗血管闭塞是有希望的。血栓并发症如中风、心肌梗死、肺栓塞、深静脉血栓形成和外周闭塞性疾病等都是导致预后不良和死亡率高的主要原因。鉴于微生物溶栓酶溶解血栓的能力,以及防止任何不良反应的能力,因此作为一种潜在的溶栓疗法引起了极大的兴趣。更好地了解止血和纤维蛋白溶解系统可能有助于提高这种治疗方法的疗效和安全性,优于经典溶栓药物。在这里,我们简要讨论了血栓形成的生理机制、血栓形成和纤维蛋白溶解、从细菌、真菌和藻类中分离出的溶栓和纤维蛋白溶解剂及其作用方式,以及微生物酶在血栓形成治疗中的潜在应用。